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barriers to diagnosis, treatment and prevention, especially in 
resource-limited settings3. These issues sit alongside addi-
tional challenges including gaps in vaccine coverage2,5, limited 
provision of diagnostic tests and treatment2 and lack of a 
curative therapy3,5. There is a growing body of personal testi-
monies providing evidence of stigma associated with HBV6,7. 
However, there is a very limited literature to describe this. We 
have therefore used the metaphor of a ‘blind spot’ to describe 
the current situation for HBV stigma. This reflects a genuine 
gap in culture or society in which there is no word for the infec-
tion, it highlights the paucity of published data, and it describes 
a problem that is known to exist, but which is often neglected or 
ignored by current interventions, policy and practice. In light of 
this, more work is required to understand the nature and impact of 
stigma for individuals with HBV infection.
Individuals who are stigmatised as a result of illness or infec-
tion not only have to contend with potential challenges to health, 
but may also be denied the opportunities that define quality of 
life such as education, employment, access to appropriate health 
care and interaction with a diverse cross-section of society8. 
Although many diseases are stigmatised, awareness of – and 
investigation into – stigma is better represented in some areas 
than others. For example, in HIV, stigma has been shown to limit 
engagement with services including screening and prevention 
of mother to child transmission (PMTCT), and uptake of antiret-
roviral therapy9–12; in tuberculosis (TB) it has been shown to 
cause diagnostic delays and treatment non-compliance13,14, and in 
mental illness, stigma has been associated with delays in help- 
seeking, discontinuation of treatment, suboptimal therapeutic 
relationships, patient safety concerns, and poorer quality mental 
and physical care15–17. 
Stereotypes and prejudice may stem from physical differences 
attributable to the condition, misconceptions associated with 
fear of contagion, and judgements about routes of transmis-
sion, all of which may be underpinned by lack of knowledge18–20 
and stigma is enhanced by poor of awareness, education and 
perception21. The importance of physical signs of illness is 
exemplified for HIV, where those displaying wasting syndrome 
and certain identifiable opportunistic infections have been 
described as suffering more stigma compared to those who are 
asymptomatic9. HIV and TB may also be stigmatised as a result of 
anxieties about spread of infection, and may be regarded as a pun-
ishment for ‘irresponsible’ or ‘immoral’ behaviour,14,22–24. People 
with mental illnesses may be considered ‘dangerous’ or provoke 
fear, may lose their autonomy, or be treated as ‘childlike’8. Under-
standing why society reacts in a particular way is one way to 
address stigma19, and could therefore help to guide approaches 
to tackling stigma in HBV.
HBV infection is highly endemic in Africa, but there are huge 
challenges in prevention, diagnosis and treatment2. The situ-
ation is further complicated by the substantial public health 
challenge of co-endemic HIV and HBV25. An understanding of 
the breadth and scope of stigma in HBV, especially in Africa, 
is an essential part of any strategy that seeks to tackle and even-
tually eliminate HBV infection as a public health problem. As 
the improvement of universal availability and accessibility of 
            Amendments from Version 1
The new version of our article includes an improved description of 
the nature of the ‘blind spot’, setting out a number of reasons why 
we have introduced this metaphor for HBV stigma.
The revision includes a PRISMA flow-chart as a main figure panel 
(previously included as supplementary data), and makes a clear 
distinction between the outcome of our systematic review of 
literature surrounding HBV (presented in the results section), vs. 
triangulation with data from other diseases associated with stigma 
(presented as discussion points).
Each article identified was appraised by two independent 
reviewers, and we revised our results tables in order to provide 
a comprehensive summary of all the data collected from these 
articles, such that any given point might be linked to multiple 
citations, thereby adding confidence to the findings.
We added a table to the results section to summarise the 32 
papers that were identified, and grouped these by geographical 
area in order to provide a clearer snapshot of the existing 
literature, as well as highlighting specifically the lack of data for 
Africa.
We undertook a quality appraisal of the literature to provide a 
better insight into the nature of the existing evidence.
We amended the discussion to mention the potential association 




•   PMTCT – Prevention of mother to child transmission
•   TB – Tuberculosis
•   HBV – Hepatitis B virus
•   HCC – Hepatocellular carcinoma
•   WHO – World Health Organization
•   HIV – Human Immunodeficiency Virus
•   HCWs – Healthcare workers
•   THs – Traditional healers
•   CHB – Chronic Hepatitis B
Introduction
Stigma is recognised as a challenge in association with many 
infectious diseases, but has been poorly studied and is inad-
equately recognised for viral hepatitis infections. Hepatitis B 
virus (HBV) infection has been reported worldwide, with an esti-
mated burden of 250–290 million cases, and has been associated 
with high mortality rates resulting from complications including 
cirrhosis and hepatocellular carcinoma (HCC)1,2. There are effec-
tive prevention and treatment strategies available, including 
vaccination and suppressive antiviral therapy, both of which also 
contribute to prevention of vertical transmission3. The Global 
Hepatitis Health Sector Strategy is aiming for the elimina-
tion of viral hepatitis as a public health threat by 20304. How-
ever, stigma, poverty, and lack of knowledge can be significant 
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diagnostic, treatment and vaccination options are underway, 
it is important to ensure that products and services are not only 
available, but also accessible; people with HBV infection must 
be able to access education, clinical care, and support from their 
partners and families, healthcare workers, and members of their 
communities. The WHO recommends HBV treatment in an 
environment that minimizes stigma and discrimination26.
We set out to assimilate evidence for the nature and impact 
of stigma on the lives of people with HBV infection and on the 
community, to describe coping strategies employed by people 
with HBV, and to suggest ways to tackle stigma and dis-
crimination. Our approach was to gather relevant information 
regarding HBV stigma from the published literature using a sys-
tematic approach, to curate it in order to unify key messages, 
and to highlight gaps where future work is still needed. We have 
been able to develop suggestions to address HBV stigma and 
discrimination from the existing literature, but in light of the 
paucity of HBV-specific studies, we have also triangulated 
our approach by drawing on resources from other stigmatised 
conditions including HIV, TB and mental illness to inform the 
discussion.
Methods
Search strategy: systematic literature review
In November-December 2017, we undertook a systematic literature 
search in PubMed; our search strategy focused entirely on the 
evidence detailing stigma in HBV (Figure 1). The terms of 
this search are detailed in Supplementary file 1. We carried 
out two searches: the first search focused on stigma in HBV in 
Africa, and a second search was not limited to Africa. The two 
searches yielded 50 and 879 articles, respectively (n=929). We 
removed 49 duplicate articles (n=880). On reviewing the titles 
and abstracts, 827 were excluded from search results as they were 
not on stigma or HBV. Full texts of 53 articles were reviewed 
by two different individuals, and 19 were excluded (6 articles 
not primary studies and 13 articles do not address stigma in 
HBV). A total of 34 articles were therefore downloaded in full. 
From each publication, we extracted the following: citation, study 
design, sample size, study population, country, factors associ-
ated with stigma, impact of stigma on the lives of people with 
HBV, and proposed interventions to tackle stigma in the society. 
We used our research question to group data collated from the 
included studies into four major themes: factors underpinning 
stigma in HBV infection, evidence for the impact of stigma, 
coping strategies for individuals with HBV infection, and 
interventions proposed to tackle stigma in HBV. There were insuf-
ficient data from Africa to focus specifically on that continent, 
but where possible we have highlighted issues that have been 
reported in African populations. Data were curated using MS 
Excel software (Microsoft, Redmond, WA). Ethics approval 
was not required for this study.
Search strategy: other relevant resources
In order to inform a wider understanding of the potential 
relevance and impact of stigma in infection and illness, we have 
Figure 1. Flow diagram illustrating identification and inclusion of studies for a systematic review of stigma in HBV, based on PRISMA 
criteria
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also referred to articles published on other conditions includ-
ing HIV, TB and mental health to underpin hypotheses set 
out in the introduction, and to inform discussion. These papers 
were not identified through a formal systematic review, but 
were identified as relevant sources from robust, peer reviewed 
literature.
Quality of evidence assessment
For the 32 studies included from our systematic review, we 
performed a risk of bias assessment (Supplementary file 2). 
For qualitative studies (n=12) we used the qualitative appraisal 
checklist by NICE public health guidance27 and for quantitative 
studies (n=19) we used the Centre of Evidence based Man-
agement checklist28. One study used a mixed method study 
design29, and we assessed this using each of the two approaches 
above. 
Results
A full list of citations generated from our systematic literature 
review of HBV stigma is shown in Table 1. We have also provided 
an expanded version of this table, with details summarising 
the key information pertinent to stigma, in Supplementary file 2.
Quality of evidence
Asia and North America were best represented by the literature, 
in contrast to Africa from where we identified only two pub-
lished studies, both set in Ghana (Table 1). Among the 19 studies 








Study design Study participants Sample size Recruitment 
site
AFRICA
Adjei et al. 2017; PMID: 
2910299130
Ghana Qualitative People with HBV infection 14 Hospital
Mkandawire et al. 2013; PMID: 
2381101231




Blanas et al. 2015; PMID: 
2500091732
USA Qualitative West African Immigrants 39 Community
Carabez et al. 2014; PMID: 
2439563133
USA Survey HBV positive Asian 
Americans
154 Community
Cheng et al. 2017; PMID: 
2777037534
USA Survey Asian 404 Community
Cotler et al. 2012; PMID: 
2223950435
USA Survey Chinese immigrants N/A Community
Frew et al. 2014; PMID: 
2550628036
USA Survey Vietnamese Americans 316 Community
Li et al. 2007; PMID: 2299372937 Canada Survey Canadian Chinese 343 Community
Russ et al. 2012; PMID: 
2244004338




Wu et al. 2009; PMID: 1917220639 Canada Survey People with HBV infection 204 Community
Yoo et al. 2012; PMID: 2174847640 USA Qualitative Asian American 23 Community
EUROPE
Cochrane et al. 2016; PMID: 
2689647241
UK Qualitative Somali community living in 
UK
30 Community
Lee et al. 2017; PMID: 
2895083542
UK Qualitative Chinese immigrants 61 Community
Sweeney et al. 2015, PMID: 
2589012543





van der Veen et al. 2014; PMID: 
2391312844
Netherlands Survey Turkish-Dutch community N/A Community
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sampling method which introduces selection bias33–35,37,45,51,59,62, 
two studies did not describe a sampling method39,58, five used 
a random sampling method36,46,47,50,61, three studies included all 
intended participants44,49,52, and only one study used a sample size 
based on pre-study consideration47. A participant response rate 
was presented in 10 studies; in nine of these the response rate was 
>60%35–37,45,49–52,59 and one had a 30% response rate44. Statistical sig-
nificance of results was reported in 15/19 studies34–37,39,44–48,51,52,59,62. 
All the qualitative studies described how concepts and themes 
were derived, presented findings clearly using extracts from 
original data and their findings were relevant to the research 
question30–32,40–43,53–56,60. All except two of these40,41 clearly 
described data collection procedure and the research context. 
Analysis of data may be less robust in four studies41,42,55,56 since 
there was no description of how many researchers analysed the 
results and how differences in extracted themes and codes were 
resolved between researchers. Two studies did not provide details 
of ethics approval40,42; three studies did not provide a rationale 
for using the selected study methodology40,43,60; seven studies did 
not report in detail on their study limitations29,42,43,53,55,56,60. For 
the single study that used mixed methodology29, a convenient 
sample was used. Participants’ response rate and statistical sig-







Study design Study participants Sample size Recruitment 
site
MIDDLE EAST AND ASIA
Dam et al. 2016; PMID: 
2810149845
Vietnam and USA Survey General population 1012 Hospital
Eguchi et al. 2013; PMID: 
2408676546
Japan Survey Japanese working community 3129 Community
Eguchi et al. 2014; PMID: 
2479209547
Japan Survey General population 3000 Community
Huang et al. 2016; PMID: 
2720637948
China Survey Individuals with HBV and 
healthy controls
1236 Community
Ishimaru et al. 2016; PMID: 
2710864549
Japan Survey Nurses 992 Hospital
Ishimaru et al. 2017; PMID: 
2916512550
Vietnam Survey Nurses 400 Hospital
Leng et al. 2016; PMID: 
2704396351
China Survey General population 903 Community
Mohammed et al. 2012; PMID: 
2285688952
Malaysia Survey People with HBV infection 483 Hospital
Ng et al. 2013; PMID: 2180763053 Malaysia Qualitative study People with HBV infection 44 Hospital
Rafique et al. 2015; PMID: 
2566451854
Pakistan Quantitive and 
qualitative study
People with HBV infection 140 Hospital
Taheri Ezbarami et al. 2017; 
PMID: 2908565755
Iran Qualitative study People with HBV infection 27 Community
Valizadeh et al. 2016; PMID: 
2698966656
Iran Qualitative study People with HBV infection 18 Hospital
Valizadeh et al. 2017; PMID: 
2836266257
Iran Qualitative study People with HBV infection 15 Hospital
Wada et al. 2016; PMID: 
2685000258
Japan Survey Nurses 992 Hospital
Wai et al. 2005; PMID: 1612405359 Singapore Survey People with HBV infection 192 Community
Wallace et al. 2017; PMID: 
2876476860
China Qualitative study People with HBV infection 41 Hospital
Yu et al. 2015; PMID: 2673313361 China Survey General population 6538 Community
AUSTRALIA
Drazic et al. 2013; PMID: 
2317132462
Australia Survey General population 77 Community
Sievert et al. 2017; PMID: 
2812013129
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arm, data collection and analysis was clearly described but 
it was not stated how many researchers analysed the data and 
how discrepancies were handled.
There was considerable diversity in the size of the popula-
tion sampled (range 14–6538), but overall, most studies had 
small sample sizes (median 173), and some were opportunistic 
in recruiting participants, thus limiting the generalisability of the 
findings.
Themes
The data that we assimilated from our literature review of 
32 systematically identified studies are presented in Table 2– 
Table 4 below.
Discussion
Through this review, we have been able to identify some key 
themes including the potentially profound impact of HBV infec-
tion on personal wellbeing and mental health, opportunities for 
education and career, influence on family and relationships, and 
the role that health care workers can play in either contributing 
to stigma or dispelling it. Through enhancing consistent insights 
into these areas, the ‘blind spot’ associated with HBV stigma 
can start to be reduced. Previous reviews addressing stigma 
in Asian populations have reported small numbers of relevant 
publications, but identify the challenges of stigma, poor knowl-
edge, and lack of focus on appropriate interventions63,64. This 
review demonstrates the lack of data for the whole of the 
African continent which is particularly striking. A recent report 
showed that in Africa, hepatocellular carcinoma (HCC) second-
ary to HBV infection frequently presents at a late stage, where 
effective treatment would be challenging for any healthcare 
system34, and indeed presentation is too late to allow formal 
diagnosis or treatment – this illustrates a hidden burden of 
infection, another aspect of the ‘blind spot’.
Stigma associated with physical disease manifestations
In most cases, HBV infection is asymptomatic and invisible 
for many decades, so individuals are not likely to be physi-
cally stigmatised. However, in acute infection, and again in 
the latter stages of chronic disease, it may cause jaundice and 
other manifestations such as abdominal swelling from ascites. 
We have not found any representation in the literature of 
stigma associated with specific physical syndromes, but further 
work is needed to explore this possibility. Importantly, health-
related quality of life, including mental health, has been shown 
to decline in the setting of more severe manifestations of HBV 
infection65.
Relationship between stigma and knowledge or education
Findings in Africa demonstrate a general lack of knowledge on 
HBV, an inability to define the disease, confusion of HBV with 
other infections, including malaria, yellow fever and HIV31,32, 
and the association of HBV symptoms with witchcraft or 
poisoning30,31. Such negative associations have been described 
to have the potential to ‘spoil the identity’ of the individual: 
the individual ceases to be perceived as a normal person but 
rather one who is tainted and discounted from society20. Lack 
of knowledge or awareness leads to misinformation that feeds 
stigma and discrimination66. Formal education can be important 
in reducing discrimination and stigma46; however, it is inter-
esting to note that this is not always the case. Indeed, higher 
levels of knowledge or formal education can sometimes be 
associated with increased stigma39,46. One study describes how 
specific knowledge - such as recognising sexual contact as a 
transmission route – can actually increase stigma32. In other 
settings, education level did not have a specific relationship with 
stigma51. A general lack of stigma was reported associated with 
HBV in the Somali population, but this study reports that the 
problem of stigma is increasing over time as education increases41.
Age may be relevant to knowledge or education, and varying 
influence of age on stigma has also been reported; in some 
instances older age and traditional values have been associated 
with stigma45,46,53 while in others, there is decreased prejudice 
among older age47. In light of these discrepancies, it is impor-
tant to design studies with bigger sample sizes and conduct 
studies in different regions and communities. This will help 
to not only provide a clear explanation of factors associated 
with stigma in HBV but will also guide in designing interven-
tions that target specific groups of people who might be most 
vulnerable to the effects of stigma.
Interventions for HBV stigma
Depending on the coping strategies used, not everyone experi-
encing stigma will necessarily suffer emotional distress or have 
diminished well-being as a consequence67. In HIV, avoidant 
coping strategies such as denial have been associated with higher 
levels of depression whereas acceptance of the diagnosis, associ-
ated with personal control and self-efficacy, is associated with 
reduced levels of depression68. Among patients with schizo-
phrenia, the ability to use positive coping strategies was 
associated with reduced self-stigma52. Stigma and/or the disease 
process can contribute to the decline of health-related quality 
of life and mental health of some individuals living with chronic 
HBV65, however there are few studies that address these issues. In 
light of this, further studies are needed to explore coping strate-
gies used to deal with HBV stigma, to explore the choice of 
coping strategy, and to determine outcomes.
As well as individual coping strategies, a variety of other inter-
ventions have been proposed to tackle stigma (Table 3). In 
many cases, attitudes may improve after realising that infection 
can be prevented and managed therapeutically37. This is in line 
with a report from the WHO about mental illness, highlighting 
that stigma can be combated through educational messages 
representing conditions as illnesses that respond to specific 
treatment46. Counselling can provide several benefits, alleviating 
anxiety associated with a new diagnosis, as well as providing an 
opportunity to share factual information regarding treatment, 
prevention, self-care and overall well-being33,49. This should be 
delivered sensitively, at a time and in a manner that supports the 
individual in accepting and processing the information.
There are several strategies that have been used to raise aware-
ness of HIV, many of which could be applied to HBV. Dissemi-
nation of factual information through use of radio, television, 
posters, pamphlets and drama has been widely used to diminish 
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    •    Lack of common cultural understanding of HBV is indicated by an absence of any word 
in local languages to define HBV31,41 and missing terms ‘hepatitis B’ and ‘carcinoma’ from 
English vocabulary in migrant populations29,41;
    •    There is confusion between HBV and other infections, including malaria, yellow fever and 
HIV31,32; HBV may be seen as synonymous with ‘jaundice’29,41,43, or believed to be associated 
with nutritional status41;
    •    One study describes the assumption that hepatitis A, B and C infections are ranked by letter 




    •    Poor understanding of the chronic nature of HBV infection, and lack of insight into the 
asymptomatic nature of HBV infection and its complications, are well described32,39,42,43,53,59;
    •   There may be an assumption that lack of symptoms correlates with lack of severity29; 
    •    Poor awareness of treatment options can be associated with a ‘passive’ or ‘fatalistic’ attitude 
towards treatment32,53;
    •    There are misconceptions that HBV screening tests can be harmful and that HBV infection 
is not treatable36;
    •    A significant correlation is reported between less knowledge and higher stigma scores34. 
However, among individuals with HBV infection, higher levels of HBV knowledge can also 
be associated with being more worried32,41,52;
    •    Improved knowledge of HBV infection is associated with higher levels of formal 
education39,52,59,61, and with a close relationship with an individual infected with HBV35.
Beliefs and insights into 
transmission of HBV infection
    •    Beliefs are widespread that HBV can be transmitted through sharing of utensils, via food 
and water, or eating together33–35,37,39,41,43,45,48,51–53,59;
    •   There is a belief that smoking tobacco causes HBV36; 
    •    Some studies report beliefs that HBV infection arises as a result of poor sanitation41,43 or 
could be transmitted by sharing water for bathing46;
    •   In some communities, HBV infection is regarded as a genetic trait34,56; 
    •    HBV infection is represented as a consequence of immoral behaviour40,42–44, or as a 
punishment for sins55;
    •    Some communities believe that HBV infection is caused by witchcraft or evil spirits; this can 
be associated with pursuit of traditional remedies or religious interventions29–31;
    •    Poor insights into transmission are associated with lack of precautions for prevention of 
transmission35,56;
    •   Awareness of injecting drug use and sexual transmission of HBV can be stigmatising32,42.
Sociodemographic factors     •    In some studies older age has been associated with increased stigma45,48,61; however, this is 
not consistent, as older age has also been associated with decreased levels of stigma47;
    •   People strongly defined by traditional values are more likely to stigmtise HBV infection55; 
    •   Unemployed individuals from rural areas are more likely to experience discrimination51,60; 
    •    HBV may be more prevalent in disadvantaged groups who are also stigmatised for other 
reasons, eg refugees29;
    •    Stigma can be reduced by having a family member with HBV infection; in this case it 
clarifies misconceptions about the disease, humanizes the affected, and can reduce 
negative attitudes associated with cultural beliefs34,35.
Interactions with HCWs     •    Lacking or inaccurate information may be provided by HCWs regarding HBV diagnosis 
or treatment, including inappropriate reassurance, or overemphasis of potential 
complications49,53;
    •    Some studies describe HCWs expressing discrimination or prejudice towards patients and/
or colleagues with HBV infection46,58, which may be more common among those who have 
poor knowledge or are unfamiliar with providing HBV care49;
    •    Diagnosis of HBV infection is presented as ‘bad news’ which can add to anxiety and stigma53,56;
    •    Lack of screening or vaccination may be associated with stigma34, although in contrast, 
HBV-related discrimination is also described as arising in association with diagnostic 
screening51.
Emotional responses     •    HBV infection can be associated with anxiety, fear and depression; see Table 3 for further 
details and references.
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stigma towards HIV in resource limited settings9. Multiple edu-
cational sessions can also be an effective way of increasing 
awareness and therefore reducing stigma, as participants have 
the opportunity to reflect on the concepts learnt in the previous 
sessions58. Another successful method for training HCWs is 
perspective-taking and empathy: participation is associated with 
‘increased willingness to treat people with certain illnesses, 
decreased stigma and increased awareness of confidentiality 
among healthcare workers’58. These approaches could be used to 
tackle HBV stigma among HCWs and community members.
On-line support groups provide a platform for people living with 
HBV to share their experiences69,70, and charities can be influ-
ential in raising awareness, and promoting important health 
messages70. The internet is widely used as a tool for sharing 
experiences, and as such can raise awareness of stigma7, as well 
as uniting individuals and communities as a support network. 
It is important for HCWs to introduce newly diagnosed individu-
als to these avenues to help people living with HBV. Importantly, 
more charities and support groups that are well suited for 
people with HBV infection in Africa are needed.
Limitations and caveats
Only two studies were identified on HBV stigma from Africa30,31; 
these studies were both carried out in one country (Ghana). Three 
other studies included African participants in USA32, Australia29 and 
in UK41. This highlights the substantial problem of HBV neglect 
in Africa. However, although we undertook a robust systematic 
search of the peer-reviewed scientific literature, there may be other 












    •   Stigma is associated with reduced uptake of opportunities for diagnostic screening and clinical care35,37,38,42,48,56,57; 
    •    There is a low rate of disclosure of HBV status among individuals with HBV to family, other acquaintances, and 
to HCWs due to fear of stigma48,55;
    •   Stigma can lead to disengagement from treatment49 and reduce treatment adherence55; 
    •    Anxiety about treatment, or the cost of treatment (potentially not just for one individual but also for other family 
members), can lead to reluctance to seek clinical care and follow-up32,49,60;
    •   Treatment can be seen as futile55; 
    •    Stigma can lead to negative experiences of health care such as being ‘labelled’, placed in physical isolation, or 
criticised by HCWs55;
    •    Stigma may influence the priorities of health professionals and commissioners, leading to certain health issues 






    •   Discrimination is reported within schools35,45; 
    •    HBV affects employment and education choices48,60; individuals with HBV infection may be discriminated 
against at work, lose employment, or be unable to find work29,34,42,54–56,60; they may also be concerned about 
missing work due to illness33, and may be restricted from particular jobs (e.g. food preparation)37,52;




    •    People with HBV infection may fear physical consequences of transmission, disease progression and/or 
treatment side effects29,51,53, including fear of cancer and death30,33,55,56;
    •   Individuals in migrant populations may fear deportation32,38; 
    •    A range of emotional responses is described, included shock and grief following initial diagnosis, and 
subsequently anxiety, sadness, denial, anger and aggression30,52,56,57,62;
    •    Negative self-image can be associated with infection, associated with feelings of disgrace, guilt and shame, 
humiliation, embarrassment, or inferiority32,34,35,39,44,48,52,53,56;
    •   Reactions can also include insomnia and depression49,53–56,60, and suicidal ideation42,54; 
    •   Anxiety is described in association with the economic cost of treatment29; 




    •    ‘Fear of contagion’ causes isolation; individuals with infection either avoid or are rejected from social activities, 
including avoidance of sharing utensils / food / towels / soap35,37,42,43,48,51,53,54,56,57,60, and may be banned from 
participation in sports55;
    •   Parents may be unwilling to allow their children to socialise with HBV-infected children51,61;
    •    Anxiety about spreading infection to family members leads to withdrawal from close relationships29,32,35,52,53,57; 
and exclusion from social gatherings60;
    •    Individuals with HBV infection perceive themselves, or are perceived by others, as less desirable as a parent or 
spouse33–35,45,48,54;
    •   Partner or spouse refuses sexual intercourse or insists on use of condoms54; 
    •    Individuals with HBV infection may seek assistance from traditional healers (THs) or faith leaders, seeking 
‘purification’; although this can provide important psychosocial support, there is also the potential for harm 
and/or delaying presentation to clinical care30.
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Sub-Saharan Africa encompasses huge diversity, and as such 
it would be misleading to assume that we can generalise about 
culture, beliefs and stigma, or that findings that arise in one 
setting can be extrapolated to others; the knowledge, manifesta-
tions, and experience of stigma is bound to be different between 
settings. It is frequently the case that local, indigenous knowl-
edge and understanding of disease and/or health conditions 
is not well reflected in the published literature. Further work 
will be needed to develop insights that are relevant to particular 
populations in order to develop the most effective interventions. 
Referring to specific examples for particular places or coun-
tries is currently difficult in the absence of more published 
data. However, to understand some of the specific challenges 
of HBV, we have previously collated individual experiences 
of HBV from patients, researchers and healthcare workers 
representing different settings across sub-Saharan Africa3.
Our description of ‘coping strategies’ is an over-simplification 
of the complex responses that arise as a result of stigma. We 
recognise that many individuals who suffer stigma may not be 
able to deploy specific active coping mechanisms, and indeed may 
‘endure’ their situation.
Future aspiration and challenges
We see this article as a starting point for this field, as it is 
currently very difficult to make substantial advances in the 
absence of better data. By collating the existing literature, we 
hope to raise the profile of this topic overall, to improve recogni-
tion of the problem, to promote dialogue, and to highlight specific 
areas of neglect. This provides a foundation for healthcare workers 
and researchers to build on over time.
Studies looking at stigma may benefit from a mixed method 
study design, providing stronger evidence and increasing 
generalisability of the findings. It is important to carry out 
research on stigma with the aim of demonstrating its burden and 
its effects, while also considering how to establish and evalu-
ate interventions that tackle stigma within communities. We 
identified only one study that evaluated the effectiveness of 
stigma reduction programmes among Asians in USA40. More 
studies like this are needed in Africa, in order to provide insights 
into local understanding and beliefs, as they will also help to 
deploy resources in the most appropriate and effective ways 
with particular relevance to individual settings. In addition to 






    •    Provision of educational opportunities in health care settings, in the individual’s own language, 
can be valuable to inform patients of the importance of symptoms, treatment, follow-up, 
prevention and social stigma32,33,43,52;
    •    Improving knowledge regarding the potential for silent complications, and understanding 
treatment could enhance willingness to access healthcare and reduce fatalism32,39;
    •    Developing positive coping strategies may include seeking encouragement from spiritual 
leaders and open dialogue with family members33,43,48,55;
    •    Lifestyle modifications can be helpful, such as reduced intake of alcohol and fatty foods30,33,52;




    •    Education and training for HCWs should be improved, particularly for community 
doctors in rural settings61; this includes training in diagnosis, prevention, treatment and 
monitoring31,33,35,37,49,53, and provision of appropriate pre- and post-test counselling29,33,49;
    •    HCWs can be deployed to design interventions to encourage participation in treatment 
programs and better self-care55;
    •    Education and communication programmes are needed to reduce stigma towards patients 
and colleagues with HBV infection49–51;
    •    Championing a positive safety culture, such as strict infection control, may not only protect 




    •    Culturally appropriate education programs are required to improve knowledge on symptoms, 
modes of transmission and preventative measures, to correct misconceptions and decrease 
stigma; this could include use of internet, social media, radio, posters in public places (bars, 
markets, healthcare settings), and should involve schools and religious leaders31–36,40,41,47–49,53,55;
    •   Specialised training on HBV for THs and ministers of faith could be a valuable approach30; 
    •    Targeting individuals directly (e.g. with letters) might be of greater benefit than mass media 
campaigns41;
    •    Developing national campaigns to promote HBV screening and vaccination as positive 
strategies that can empower local communities in their own healthcare40,53;
    •    Establishing a human connection can increase familiarity and reduce apprehension and 
negativity42; for example, high profile public advocates have been successful in the ‘B Free 
Campaign’34,40;
    •    National strategic responses to HBV infection should specifically acknowledge and address 
the social implications of the infection60, and should prioritise affordability of prevention and 
treatment36.
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general public and HCWs, enhanced communication with policy 
makers is also crucial. Despite the high burden of HBV 
in low and middle-income countries, there is limited infrastruc-
ture to support diagnosis and treatment, and disproportionately 
little international research funding for HBV compared to other 
infectious diseases3.
Conclusion
Despite the limited evidence from Africa, the data we have 
gathered reflect consistent themes in stigma and discrimina-
tion affecting individuals with chronic viral hepatitis infection. 
These may have a wide-reaching influence on physical health 
(for example inhibiting interaction with clinical services and 
reducing treatment adherence), psychological well-being (through 
increasing isolation, anxiety and depression), and interactions 
with family and the wider society (by limiting relationships, 
social interactions and employment opportunities). Recognising, 
understanding and tackling the issue of this stigma in African 
populations could be a valuable tool to improve population 
health and to underpin advances towards elimination strategies 
proposed for the year 2030. Education clearly provides a very 
important role in reducing discrimination and stigma; it is 
interesting to note that stigma may drive lack of knowledge, just 
as lack of knowledge may drive stigma.
There is also a pressing need for more research in this area, to 
identify and evaluate interventions that can be used effectively 
to tackle stigma in HBV, and for collaborative efforts between 
policy makers, HCWs, traditional healers, religious leaders, 
charity organisations and support groups, to improve awareness 
and tackle stigma in HBV in Africa.
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